Healthcare Equipment and Supplies
Company Overview of Singulex, Inc.
Singulex, Inc. develops and manufactures immunodiagnostic products. It provides immunoassay systems, which includes benchtop analytical instrumentation, integrated and prepared reagents for ultrasensitive immunoassays, and software to automatically analyze data and display detailed assay reports. The company also offers molecule counting products; ultrasensitive immunoassays, such as inflammation, cardiovascular, neurology, oncology, metabolism, and toxicity; SgxHD for cardiovascular monitoring; and custom services and support, such as sample testing, assay development, and antibody derivatization. Singulex, Inc. was formerly known as BioProfile Corporation and changed its name to Singulex, ...
1650 Harbor Bay Parkway
Alameda, CA 94502
Founded in 1997
Key Executives for Singulex, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Principal Accounting Officer
Chief Commercial Officer and Senior Vice President of Sales & Marketing
Vice President of Business Development
Compensation as of Fiscal Year 2015.
Singulex, Inc. Key Developments
Singulex Demonstrates Ultrasensitive "Sgx Clarity(TM) System" at AACC 2015
Jul 14 15
Singulex, Inc. announced that it will demonstrate the "Sgx Clarity System" in the company booth at the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting from July 26 to 30, 2015 (booth number #2758). Utilizing Singulex's proprietary second generation SMC technology, the fully-automated Sgx Clarity System is designed to detect low abundance biomarkers at levels down to femtograms/mL. The Sgx Clarity System is on track for full commercialization in Europe in 2016. In addition, the company highlighted multiple scientific presentations that will take place at the AACC meeting that demonstrate the ultrasensitive protein detection of SMC technology using prototypes of the Sgx Clarity System (the Sgx Clarity System is in development; not available for commercial sale). Importantly, the abstract entitled High-sensitivity cardiac troponin I in a large community-based population at risk for cardiovascular disease won a National Academy of Clinical Biochemistry (NACB) Distinguished Abstract Award. Each year, the NACB, the professional arm of the American Association for Clinical Chemistry, acknowledges several posters to be presented with an NACB distinction. In Dr. Alan Wu's poster, research that evaluated ultrasensitive cardiac troponin I (hs-cTnI) levels from 23,000 patients' blood samples, processed and analyzed using Singulex's SMC technology, highlights the impact of comorbidities on heart disease. The research concluded that differences in hs-cTnI levels exist between age and gender which may represent subclinical disease. Moreover, it may be possible to establish hs-cTnI concentrations for subgroups of patients that may more accurately define patients at risk for cardiovascular disease.
Merck Millipore Enters into Agreement to Acquire Exclusive Rights to Singulex's Ultra-Sensitive Single Molecule Counting Technology
May 21 15
Merck Millipore and Singulex announced that they have entered into a definitive agreement under which Merck Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, Merck Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. Merck Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide. Reliable, ultra-sensitive protein detection is a critical unmet need in life science research. Current technologies allow detection of only approximately 5% of proteins in the entire proteome due to the very low abundance of many biomarkers, leaving the vast majority of proteins virtually undetectable. The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits of this technology have been well-established and Singulex will continue to operate a large and successful clinical service business based on novel, enabling SMC assays. Financial and other terms of the deal were not disclosed.
Singulex Announces Collaboration with CHDI Foundation to Develop Biomarker Assays for Huntington's Disease
Apr 9 15
Singulex, Inc. announced a collaboration agreement with CHDI Foundation. The collaboration will use Singulex's proprietary Erenna Immunoassay System to develop biomarkers to further Huntington's disease research. The Singulex assay combines fluorescent antibodies with a laser detection chamber to count individual molecules of mHTT with a very low detection threshold, including both high specificity for mHTT and sensitivity to the femtomolar level.
Similar Private Companies By Industry
Recent Private Companies Transactions